Printer Friendly

SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE THAT CPMP RECOMMENDS APPROVAL 'LEUCOMAX' IN EUROPEAN COMMUNITY

 SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE THAT CPMP
 RECOMMENDS APPROVAL 'LEUCOMAX' IN EUROPEAN COMMUNITY
 MADISON, N.J., Sept. 10 /PRNewswire/ -- Schering-Plough Corporation of Madison, and Sandoz Pharma Ltd. of Basel, Switzerland, today announced that the European Community's Committee for Proprietary Medicinal Products (CPMP) has recommended approval of 'Leucomax' (molgramostim), a granulocyte macrophage colony stimulating factor (GM-CSF). The medication was jointly developed by Sandoz and Schering- Plough and will be co-marketed in the European Community (EC) by the two companies.
 GM-CSF is one of a group of natural proteins that broadly stimulate the production of white blood cells, a key element of the body's defense against infection.
 The CPMP recommended that 'Leucomax' be approved for chemotherapy- induced neutropenia in cancer patients, to accelerate recovery after autologous bone marrow transplantation, and to combat gancyclovir (DHPG)-induced neutropenia in AIDS patients with cytomegalovirus retinitis, which in most cases leads to blindness. The application was based on controlled clinical studies involving over 1,500 patients.
 The 'Leucomax' application was filed in August 1990 with the Medicines Control Agency of the United Kingdom, which served as the rapporteur country for the CPMP. The CPMP is the EC body for the review of applications for biotechnology and high-technology products.
 "The CPMP's recommendation to EC countries represents a major step toward bringing 'Leucomax' to the European marketplace," said Richard J. Kogan, Schering-Plough president and chief operating officer. "'Leucomax' is a new form of adjuvant therapy that can reduce the morbidity of cancer therapy and lessen the risk of infection in patients with low white blood cell counts."
 According to Dr. Max Link, chairman, Sandoz Pharma: "'Leucomax' belongs to the family of drugs known as cytokines. A key objective for such innovative treatments is to improve tolerance to chemotherapy, with the ultimate goal of greater patient survival and quality of life."
 'Leucomax' is currently marketed in Argentina, Mexico and Sweden, and approved for marketing in Chile, Ecuador, Finland, Israel, Pakistan and Russia. Schering-Plough and Sandoz have filed marketing applications for 'Leucomax' in most major countries.
 Sandoz and Schering-Plough are research-based companies engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.
 -0- 9/10/92
 /CONTACT: Steve Galpin, Jr. of Schering-Plough Corp., 201-822-7415, or Charles Pitts of Sandoz Pharma, 011-41-61-324-62-72/
 (SGP) CO: Schering-Plough Corporation; Sandoz Pharma Ltd. ST: New Jersey IN: MTC SU:


SM -- NY032 -- 7926 09/10/92 10:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 1992
Words:395
Previous Article:SQUARE D READIES TO HELP RESTORE POWER IN HURRICANE'S PATH
Next Article:FPL HURRICANE ANDREW OVERVIEW
Topics:


Related Articles
SCHERING-PLOUGH BRIEFS ANALYSTS ON RESEARCH PROGRESS, NEW PRODUCTS
SCHERING-PLOUGH SIGNS WORLDWIDE AGREEMENT TO DEVELOP AND MARKET CANCER DRUG
SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE U.K. LAUNCH OF 'LEUCOMAX'
SCHERING-PLOUGH AND CELLTECH IN AGREEMENT TO DEVELOP ANTIBODIES TO CYTOKINES
SCHERING-PLOUGH AND U.S. BIOSCIENCE
SCHERING-PLOUGH ANNOUNCES THAT CPMP ISSUES POSITIVE RECOMMENDATION ON TALOXA (FELBAMATE), A NEW EPILEPSY AGENT, IN EUROPEAN UNION
SCHERING-PLOUGH AND ORION SIGN AGREEMENT ON U.S. MARKETING RIGHTS FOR BREAST CANCER TREATMENT
SCHERING-PLOUGH ANNOUNCES FARESTON; RECEIVES EU MARKETING AUTHORIZATION FOR TREATING ADVANCED BREAST CANCER
Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine for Seasonal Allergies.
Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine Syrup and Rapidly Disintegrating Tablets.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters